Soligenix Inc. (SNGX) - Total Assets
Based on the latest financial reports, Soligenix Inc. (SNGX) holds total assets worth $11.29 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Soligenix Inc. to assess the company's total reinvestment commitment from operating cash flow.
Soligenix Inc. - Total Assets Trend (1995–2024)
This chart illustrates how Soligenix Inc.'s total assets have evolved over time, based on quarterly financial data. Check Soligenix Inc. (SNGX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Soligenix Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Soligenix Inc.'s total assets of $11.29 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Soligenix Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Soligenix Inc. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Soligenix Inc.'s current assets represent 98.5% of total assets in 2024, an increase from 74.3% in 1995.
- Cash Position: Cash and equivalents constituted 87.2% of total assets in 2024, up from 71.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 12.0% in 1995.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Soligenix Inc. Competitors by Total Assets
Key competitors of Soligenix Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Soligenix Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.18 | 2.28 | 3.20 |
| Quick Ratio | 3.18 | 2.28 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.46 Million | $5.78 Million | $13.39 Million |
Soligenix Inc. - Advanced Valuation Insights
This section examines the relationship between Soligenix Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | $8.97 Million |
| Market Capitalization | $4.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Soligenix Inc.'s assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Soligenix Inc.'s assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Soligenix Inc. (1995–2024)
The table below shows the annual total assets of Soligenix Inc. from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.97 Million | -8.48% |
| 2023-12-31 | $9.80 Million | -31.39% |
| 2022-12-31 | $14.28 Million | -46.86% |
| 2021-12-31 | $26.87 Million | +35.08% |
| 2020-12-31 | $19.89 Million | +155.82% |
| 2019-12-31 | $7.78 Million | -25.89% |
| 2018-12-31 | $10.49 Million | +9.86% |
| 2017-12-31 | $9.55 Million | -6.99% |
| 2016-12-31 | $10.27 Million | +38.99% |
| 2015-12-31 | $7.39 Million | +6.22% |
| 2014-12-31 | $6.95 Million | -15.86% |
| 2013-12-31 | $8.27 Million | +75.67% |
| 2012-12-31 | $4.71 Million | -42.79% |
| 2011-12-31 | $8.22 Million | -11.27% |
| 2010-12-31 | $9.27 Million | -1.23% |
| 2009-12-31 | $9.38 Million | +179.07% |
| 2008-12-31 | $3.36 Million | -11.13% |
| 2007-12-31 | $3.78 Million | +168.94% |
| 2006-12-31 | $1.41 Million | -58.28% |
| 2005-12-31 | $3.37 Million | -33.45% |
| 2004-12-31 | $5.07 Million | -18.94% |
| 2003-12-31 | $6.25 Million | +7.09% |
| 2002-12-31 | $5.84 Million | -47.13% |
| 2001-12-31 | $11.04 Million | -19.22% |
| 2000-12-31 | $13.67 Million | +47.43% |
| 1999-12-31 | $9.27 Million | -42.76% |
| 1998-12-31 | $16.20 Million | -15.18% |
| 1997-12-31 | $19.10 Million | +1428.00% |
| 1996-12-31 | $1.25 Million | -12.93% |
| 1995-12-31 | $1.44 Million | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more